Menu Search
Equities

CSPC Pharmaceutical Group Ltd

1093:HKG.HZ

CSPC Pharmaceutical Group Ltd

Actions
  • Price (HKD)5.84
  • Today's Change-0.05 / -0.85%
  • Shares traded24.10m
  • 1 Year change-8.18%
  • Beta--
Data delayed at least 15 minutes, as of Jul 25 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

CSPC Pharmaceutical Group Ltd is an investment holding company primarily engaged in the manufacture and sale of pharmaceutical products. The Company operates its business through three segments. The Finished Drugs segment in engaged in the research and development, manufacture and sale of pharmaceutical products and licensing business. The Bulk Products segment is engaged in the manufacture and sale of vitamin C, and antibiotic products in bulk powder form. The Functional Food and Others segment is engaged in the manufacture and sale of functional food products (including caffeine food additives, anhydrous glucose, acarbose and vitamin C buccal tablets), provision of healthcare service and others. The Company’s product therapeutic areas include nervous system, oncology, anti-infectives, cardiovascular, respiratory system, digestion and metabolism and others. The Company conducts its business in the domestic and overseas markets.

  • Revenue in HKD (TTM)34.81bn
  • Net income in HKD6.51bn
  • Incorporated1992
  • Employees23.50k
  • Location
    CSPC Pharmaceutical Group LtdNo. 226 Huanghe StreetSHIJIAZHUANG 050035ChinaCHN
  • Phone+86 31 187037015
  • Fax+86 31 187039608
  • Websitehttps://www.cspc.com.hk/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.